One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
InspireMD, Inc.
NSPR · NCM · Healthcare · Medical Devices
Current price
$0.70
52-week range
$0.63 - $2.57
Market cap
$32.79M
Balance sheet
Healthy
-316.01x Concerning
Net cash $27.40M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
2 Risks
1 rewards · 2 risks
- Reward Revenue grew 20.7% last year.
- Risk Operating margin compressed from -361.9% to -815.6% over 3 years.
- Risk Return on equity was -202.8% last year — the company lost money on shareholders' equity.
What this company does
InspireMD, Inc.
InspireMD is a medical device company that makes products to treat blocked neck arteries, a major cause of strokes. It earns money by selling its main product, a special mesh tube called the CGuard stent (a tiny tube that props open a blood vessel), to hospitals around the world. The company's future success depends on convincing more doctors that its devices are a safer and better option for these critical procedures.
How the company got here
InspireMD was founded in 2005 to create medical devices for treating blocked arteries. A key moment in its history was the development of its special MicroNet technology, a very fine mesh designed to make artery-opening procedures safer. For many years, the company focused on getting approval to sell its products in Europe and other international markets. A major turning point came recently with the U.S. Food and Drug Administration (FDA) approval of its CGuard Prime stent system, allowing it to enter the large American healthcare market.
What it actually does
InspireMD creates and sells tiny, expandable tubes called stents, which doctors use to open up narrowed carotid arteries, the main blood vessels in the neck that supply blood to the brain. When these arteries get clogged with a substance called plaque, it can increase the risk of a stroke. InspireMD's stents are unique because they are covered in a microscopic mesh net. This net is designed to trap any small pieces of plaque that might break loose during the procedure, preventing them from traveling to the brain and causing a stroke.
CGuard Carotid Stent Systems
This is the company's single line of business and accounts for all of its revenue (the money it makes from sales). It sells its CGuard family of products, including the newer CGuard Prime, directly to hospitals and medical distributors. Doctors use these devices in a procedure to widen a patient's narrowed neck artery. The company's main selling point is the added safety provided by its MicroNet mesh. While InspireMD has been selling its products internationally for some time, sales in the U.S. are a new and important part of its business.
What management is betting on now
The company's leadership is focused on the successful commercial launch of its CGuard Prime system in the United States, which is a top priority. They are also seeking to expand the approved uses of their device, particularly for a less invasive procedure known as TCAR (transcarotid artery revascularization), which could significantly increase the number of patients who could be treated with their product. Continuing to grow sales in international markets and developing new devices based on their core MicroNet technology are also key parts of their strategy. Management has provided guidance (a company's projection of its future performance) for significant revenue growth, driven by increasing adoption in the U.S.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-6.12M
FY2024 Q4
$-7.06M
FY2025 Q1
$-9.15M
FY2025 Q2
$-8.91M
FY2025 Q3
$-8.96M
FY2025 Q4
$-9.74M
FY2026 Q1
$-12.53M
FY2026 Q2
$-11.22M
Revenue
$1.77M
Net income
$-14.32M
Diluted EPS
-0.17
Operating cash flow
$-10.89M
Free cash flow
$-11.22M
Fetching…
Sources
Revenue
$3.40M
Net income
$-13.69M
Diluted EPS
-0.16
Operating cash flow
$-12.34M
Free cash flow
$-12.53M
Fetching…
Sources
Revenue
$3.15M
Net income
$-11.76M
Diluted EPS
-0.11
Operating cash flow
$-9.35M
Free cash flow
$-9.74M
Fetching…
Sources
Revenue
$2.52M
Net income
$-12.71M
Diluted EPS
-0.17
Operating cash flow
$-8.63M
Free cash flow
$-8.96M
Fetching…
Sources
Revenue
$1.78M
Net income
$-13.15M
Diluted EPS
-0.26
Operating cash flow
$-8.33M
Free cash flow
$-8.91M
Fetching…
Sources
Revenue
$1.53M
Net income
$-11.17M
Diluted EPS
-0.22
Operating cash flow
$-8.79M
Free cash flow
$-9.15M
Fetching…
Sources
Revenue
$1.95M
Net income
$-9.17M
Diluted EPS
-0.17
Operating cash flow
$-6.75M
Free cash flow
$-7.06M
Fetching…
Sources
Revenue
$1.81M
Net income
$-7.89M
Diluted EPS
-0.16
Operating cash flow
$-5.70M
Free cash flow
$-6.12M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.70
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $27.4M - more cash than debt. Interest coverage -316.0x.
Net debt
$-27.40M
Interest coverage
-316.01x
InspireMD, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
NSPR
BASELINE
InspireMD, Inc.
Total debt $3.02M Interest coverage -316.01x This is the baseline the peer rows are being compared against.
Total debt $175.34K Interest coverage -12.65x Neither company has much profit cushion over interest right now.
Total debt $134.00K Interest coverage -392.74x Neither company has much profit cushion over interest right now.
Total debt $26.01M Interest coverage 1.98x This peer still has a real interest-payment cushion, while NSPR does not.
Total debt $59.39M Interest coverage -8.80x Neither company has much profit cushion over interest right now.
Total debt $39.63M Interest coverage -1.15x Neither company has much profit cushion over interest right now.
What you should know
The case for and against NSPR
1 Reward
2 Risks
Rewards
-
Revenue grew 20.7% last year.
Risks
-
Operating margin compressed from -361.9% to -815.6% over 3 years.
-
Return on equity was -202.8% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.45x
P/B
1.04x
P/S
3.02x
EV/EBITDA
-0.10x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
18.1%
Operating margin
-815.6%
Net margin
0.0%
ROE
-202.8%
ROA
-85.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.10x
Current ratio
3.80x
Quick ratio
3.40x
Total debt
$3.02M
Total cash
$30.42M
Growth
How the business has been compounding
Revenue TTM
$10.84M
Revenue 5Y CAGR
18.9%
EPS TTM
-0.61
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-41.21M
Free CF TTM
$-36.77M
FCF margin
-339.1%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—